Sector News

After a round trip, ex-Intellia CEO Bermingham lands back at Atlas

February 6, 2018
Life sciences

A couple of months ago, Intellia’s leader and founder Nessan Bermingham, Ph.D., left the CRISPR company, but we knew not where.

Today, we found out, and there is little surprise on this occasion as Bermingham has returned full circle, back at Atlas Ventures, the firm that also helped launch Intellia, one of a handful of U.S. biotechs hoping to make good on the early promise of CRISPR gene editing. He first started at the VC firm back in 2002.

Nessan will now be involved “with the formation and leadership of ground-breaking new biotechnology companies as part of the Atlas platform,” the firm said in a brief statement.

“I am thrilled to be working with Atlas again as we translate cutting-edge scientific advances into medicines for patients in need and build great companies,” says Bermingham.

Bermingham co-founded Intellia with Atlas back in 2014, leading the company from its seed investment and incubation at Atlas through to its $108 million IPO.

He first joined Atlas in 2002 and worked on multiple Atlas portfolio companies across various stages

“Nessan is a relentless entrepreneur and operator who has proven his ability to build breakthrough biotech companies from the ground up,” said Jean François Formela, partner at Atlas.

“We are excited to welcome him back to Atlas and look forward to creating transformational new companies with him.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).